Novel Emergent Treatment Choice For Preliminary Lung Cancer Stage

Those ailing from preliminary stage, non-resectable lung cancer that could not be surgically operated upon, would henceforth have a potent treatment choice. Physicians vouch for the efficacy of the radical stereotactic radiosurgery conducted with the aid of CyberKnife that has a hundred percent general survival following 3 years among those patients having normally functioning lung prior to the treatment.

The outcome of the study was lately presented at the yearly CHEST conference held in San Diego. The study has garnered a spot in the semi-final round for an Alfred Soffer Research Award, chosen for ‘outstanding original scientific research’.

In patients having small-sized tumors typified as preliminary-stage cancer, surgical excision of the cancerous lobe by employing lobectomy is the usual line of treatment. But, surgery cannot be attempted in many situations due to the presence of other already existing medical conditions like emphysema or heart ailment.

A radiation oncologist at the Lombardi Comprehensive Cancer Center at Georgetown University Hospital, Brian T. Collins, MD, who helmed the study, expressed how their objective has always been to decode a viable choice for those patients that didn’t desire or could not endure surgery. He further explicated how this discovery holds immense potential and could hold relevance among patients having stage one lung cancer. Further follow-up sessions with these patients are on the cards to keep tabs on their progress for 5 years subsequent to the treatment.

Among the 24 entrants that were part of the study, the FEV1 or Forced Expiratory Volume in one second was calculated for each of them.

Eric D. Anderson, MD, a pulmonologist from Georgetown University Hospital and also the presenter for the summary elucidated how they employed the FEV1 for grading how severe the level of the patient’s COPD (Chronic Obstructive Pulmonary Disease or widely known as emphysema) was by measuring the patient’s capacity to breathe out cogently.

On the basis of the average follow-up conducted for a span of three years, the general survival rate in these patients was observed to be seventy-nine percent and 5 fatalities taking place because of the proliferating lung dysfunction. Those patients that exhibited comparatively better FEV1 had a survival of hundred percent.

Collins stated that the treatment showed ample tolerance among patients undergoing it, with just slight exhaustion cited in most of the patients. The researchers also deciphered that those patients having depleted lung functioning did not fare well in the study with a general survival rate being just thirty percent.

This data was crucial for both the physician and the patient when choosing which treatment to perform. Collins stated that those with poorly functioning lung, the appropriate treatment would be to alter the treatment dosage for lowering further harm to the lungs that is caused by stereotactic surgery.

According to the American Cancer Society, Lung Cancer is the widespread cause of cancer fatalities wherein more than two lakh individuals get detected annually and nearly 1,61,804 fatalities occur due to the disease. With no scanning tests obtainable for lung cancer that would help in early detection when it could be mostly cured, few tumors are detected early due to medical tests that are conducted for other reasons.

The outcome is significant as lung cancer is characteristically the outcome of long-standing smoking that leads to health issues such as emphysema. In such patients, conventional lung surgery could have grave repercussions as they might be having other health problems. This study reveals that CyberKnife is a feasible and promising choice for those in whom the lung tumor has not reached the lymph nodes or the remote body parts and in whom surgery is quite risky.

The study was backed by the CyberKnife Society. Collins reported getting reimbursement for clinical consulting by ACCURAY, the creator of the CyberKnife.

Popularity: 21% [?]